Stratification of Dementia with Biomarkers for Amyloid, Tau and other Neuropathological changes - SD-BATO

akamura Akinori0 sites450 target enrollmentAugust 30, 2021

Overview

No summary available.

Registry

who.int

Start Date

August 30, 2021

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

akamura Akinori

•Cognitively unimpaired individuals:A person who has no complaint about memory, and those who have complaints but do not show obvious abnormalities in cognitive function tests. Age is 20 to 90 years old, regardless of gender.
•Patients: AD, MCI, DLB, FTLD, VaD, PSP, CBS, PPA, iNPH, elderly tauopathy, and other neurodegenerative diseases that cause dementia. Age is up to 90 years (regardless of age limit and gender)
•1\) Written informed consent is obtained. If a subject's cognitive ability is considered to be declined to understand the consent, his/her family or legally acceptable representative must provide the written informed consent.
•2\) A subject with good general condition, who has no problem to perform all necessary examinations.
•3\) Community\-dwelling individuals and outpatients of the hospitals which are involved in the project. Participants for the J\-TRC and Nagoya University cohort clinical studies who meet the participation criteria for this study with reference to the test results already conducted.
•4\) Participants for the NCGG\-SGS cohort who meet the participation criteria of this research with reference to the test results that have already been conducted.

•1\) Clinical history of brain tumors, traumatic brain injury, or progressive neurodegenerative disorders other than dementia. However, cerebrovascular dementia is not excluded.
•2\) Use of medications with antidepressants or antipsychotics. History of alcohol or other drug addiction. Any uncontrolled significant medical condition, abnormal thyroid function, vitamin B1 deficiency, or vitaminB12 deficiency. Use of therapeutic agents for dementia such as donepezil and galantamine does not affect the selection of subjects.
•3\) Significant deformity/disorders of the spine or hip joint that causes pain or discomfort during examinations.
•4\) Contraindications to MRI imaging such as, internal implants that operate electrically, magnetically or mechanically. E.g., cardiac pacemakers, internal nerve stimulators, bone growth stimulators, internal defibrillators, and cochlear implants.